Tags

Type your tag names separated by a space and hit enter

Combination therapy with statins and omega-3 fatty acids.
Am J Cardiol. 2006 Aug 21; 98(4A):34i-38i.AJ

Abstract

Combined dyslipidemia is the concurrent presence of multiple abnormalities in various lipid subfractions, including elevated concentrations of low-density lipoprotein (LDL) cholesterol and triglycerides (TGs), as well as decreased concentrations of high-density lipoprotein (HDL) cholesterol. The Adult Treatment Panel III (ATP III) guidelines of the US National Cholesterol Education Program (NCEP) lowered the cut points for classification of TG levels, established non-HDL cholesterol levels as a secondary target of therapy in patients with TGs of >or=2.26 mmol/L (200 mg/dL), and defined the metabolic syndrome as a secondary target of therapy. Although 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are first-line therapy for most patients with elevated LDL cholesterol, statin monotherapy may not be sufficient to achieve recommended non-HDL cholesterol goals, and statins have only modest effects on reducing TG levels. Similarly, patients whose TG levels remain elevated despite treatment with a TG-lowering agent may require the addition of a statin to provide further TG reduction. In addition, statin therapy may be needed to offset the secondary increase in levels of LDL cholesterol that frequently results from treatment with a TG-lowering agent in patients with marked hypertriglyceridemia. In a number of small studies, the combination of statins and omega-3 fatty acids has been consistently shown to be an effective, safe, and well-tolerated treatment for combined dyslipidemia. Patients with recent myocardial infarction may also benefit from this combination. When considering risks and benefits of adding a second agent to statins for treatment of combined dyslipidemia, omega-3 fatty acids provide additional lipid improvements without requiring additional laboratory tests and do not increase risk for adverse muscle or liver effects.

Links

Publisher Full Text

Authors+Show Affiliations

Nambi V
Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Ballantyne CM
No affiliation info available

MeSH

Anti-Inflammatory AgentsCholesterol, HDLCholesterol, LDLCombined Modality TherapyDyslipidemiasFatty Acids, Omega-3Fibrinolytic AgentsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMyocardial InfarctionPractice Guidelines as TopicTriglycerides

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16919515

Citation

Nambi, Vijay, and Christie M. Ballantyne. "Combination Therapy With Statins and Omega-3 Fatty Acids." The American Journal of Cardiology, vol. 98, no. 4A, 2006, pp. 34i-38i.
Nambi V, Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol. 2006;98(4A):34i-38i.
Nambi, V., & Ballantyne, C. M. (2006). Combination therapy with statins and omega-3 fatty acids. The American Journal of Cardiology, 98(4A), 34i-38i.
Nambi V, Ballantyne CM. Combination Therapy With Statins and Omega-3 Fatty Acids. Am J Cardiol. 2006 Aug 21;98(4A):34i-38i. PubMed PMID: 16919515.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combination therapy with statins and omega-3 fatty acids. AU - Nambi,Vijay, AU - Ballantyne,Christie M, Y1 - 2006/05/30/ PY - 2006/8/22/pubmed PY - 2006/9/29/medline PY - 2006/8/22/entrez SP - 34i EP - 38i JF - The American journal of cardiology JO - Am J Cardiol VL - 98 IS - 4A N2 - Combined dyslipidemia is the concurrent presence of multiple abnormalities in various lipid subfractions, including elevated concentrations of low-density lipoprotein (LDL) cholesterol and triglycerides (TGs), as well as decreased concentrations of high-density lipoprotein (HDL) cholesterol. The Adult Treatment Panel III (ATP III) guidelines of the US National Cholesterol Education Program (NCEP) lowered the cut points for classification of TG levels, established non-HDL cholesterol levels as a secondary target of therapy in patients with TGs of >or=2.26 mmol/L (200 mg/dL), and defined the metabolic syndrome as a secondary target of therapy. Although 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are first-line therapy for most patients with elevated LDL cholesterol, statin monotherapy may not be sufficient to achieve recommended non-HDL cholesterol goals, and statins have only modest effects on reducing TG levels. Similarly, patients whose TG levels remain elevated despite treatment with a TG-lowering agent may require the addition of a statin to provide further TG reduction. In addition, statin therapy may be needed to offset the secondary increase in levels of LDL cholesterol that frequently results from treatment with a TG-lowering agent in patients with marked hypertriglyceridemia. In a number of small studies, the combination of statins and omega-3 fatty acids has been consistently shown to be an effective, safe, and well-tolerated treatment for combined dyslipidemia. Patients with recent myocardial infarction may also benefit from this combination. When considering risks and benefits of adding a second agent to statins for treatment of combined dyslipidemia, omega-3 fatty acids provide additional lipid improvements without requiring additional laboratory tests and do not increase risk for adverse muscle or liver effects. SN - 0002-9149 UR - https://www.unboundmedicine.com/medline/citation/16919515/Combination_therapy_with_statins_and_omega_3_fatty_acids_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(05)02188-0 DB - PRIME DP - Unbound Medicine ER -